OMass Therapeutics Announces £27.5 Million Extended Series A Financing
Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders.
We publish news of technology innovations, investment opportunities, together with updates from spin-out & start-up companies and licensees
Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders.
Leading angel networks in Oxford merge to catalyse early-stage tech investment in the Oxford Cluster.
Y Combinator startup Prolific announces $1.2M seed round with participation from Pioneer Fund and prominent Silicon Valley Angel investors.
Oxford spinout developing novel therapeutics based on deep expertise in immune cell regulation.
LAB10x launched and AI@Oxford on the horizon in another active quarter for the Oxford Innovation Ecosystem.
Osage University Partners and Oxford University Innovation sign MoU on investment into Oxford University spinouts.
LAB10x aims to accelerate the commercialisation of the next generation of digital therapeutics and data-driven drug discovery from clinical artificial intelligence research and digital health innovations at Oxford University